VivaMed BioPharma and CRDMO Syngene International are partnering on artificial intelligence (AI)-powered discovery to bolster VivaMed’s validation infrastructure. As a clinical-stage pharmaceutical company, VivaMed uses AI for discovery and advancement of repurposed and improved therapeutic assets.

Accordingly, the collaboration with Syngene aims to expand VivaMed’s validation infrastructure. The eventual goal is to deliver scientifically validated and partner-ready therapeutic programs.

How AI Assists Validation

As a result of the partnership, Syngene’s preclinical development capabilities will integrate with VivaMed’s AI-derived therapeutic hypotheses.

In a press release, VivaMed presented three pillars to accomplish this.

The first is AI-powered discovery. This incorporates a proprietary AI engine that is amplified by a global network of co-scientists.

After that, the second pillar is rigorous validation. VivaMed enhances that framework with in-vitro and in-vivo pharmacology studies, biomarker confirmation, and assay development among other elements.

Finally, the third pillar, strategic commercialization, aligns with pharmaceutical partner priorities to create de-risked and scalable development opportunities.

VivaMed, Syngene Leaders Respond

“AI-driven discovery must be matched with rigorous experimental execution,” said VivaMed CEO Kendric Speagle.

Speagle said the partnership with Syngene strengthens VivaMed’s validation engine.

“[It] ensures that our most promising programs are developed with the scientific depth and operational discipline required,” Speagle said.

VivaMed President and CMO John Shufeldt said the company’s assets should not only be scientifically compelling, but also operationally aligned.

“Strategic partnerships like this one create a scalable foundation for continued collaboration,” Shufeldt said.

Kenneth Barr, Syngene Senior Vice President and Head of Strategic Collaborations, said it translates high-throughput research into credible therapeutic candidates.

“This partnership strengthens our ability to apply a scaled drug development model to repurposed assets,” Barr said.

VivaMed wishes to continue expanding its network of research, validation, and commercialization collaborators. To that end, the company seeks more relationships with contract research organizations, academic institutions, and pharmaceutical partners.